The Insider, Sharon Shacham Sold 10,000 Shares of Karyopharm Therapeutics Inc. (KPTI); Rivernorth Capital Management Increased By $1.20 Million Its Garrison Cap (GARS) Stake

Rivernorth Capital Management Llc increased Garrison Cap Inc (GARS) stake by 16.52% reported in 2017Q4 SEC filing. Rivernorth Capital Management Llc acquired 150,407 shares as Garrison Cap Inc (GARS)’s stock declined 0.86%. The Rivernorth Capital Management Llc holds 1.06 million shares with $8.60 million value, up from 910,217 last quarter. Garrison Cap Inc now has $136.10M valuation. The stock increased 0.83% or $0.07 during the last trading session, reaching $8.48. About 25,769 shares traded. Garrison Capital Inc. (NASDAQ:GARS) has declined 14.99% since May 22, 2017 and is downtrending. It has underperformed by 26.54% the S&P500.

Rivernorth Capital Management Llc decreased Blackrock Debt Strat Fd Inc stake by 187,555 shares to 1.55 million valued at $18.22 million in 2017Q4. It also reduced Blackrock Ltd Duration Inc T (NYSE:BLW) stake by 47,520 shares and now owns 179,684 shares. Brookfield Real Assets Incom was reduced too.

Among 6 analysts covering Garrison Capital (NASDAQ:GARS), 2 have Buy rating, 0 Sell and 4 Hold. Therefore 33% are positive. Garrison Capital had 17 analyst reports since August 5, 2015 according to SRatingsIntel. As per Friday, August 12, the company rating was downgraded by Robert W. Baird. Stephens maintained the stock with “Overweight” rating in Thursday, March 17 report. The stock has “Buy” rating by Maxim Group on Monday, November 9. The stock has “Buy” rating by Maxim Group on Thursday, May 10. The rating was maintained by Maxim Group with “Buy” on Thursday, November 9. The stock has “Buy” rating by Maxim Group on Thursday, August 10. Maxim Group maintained Garrison Capital Inc. (NASDAQ:GARS) on Friday, March 9 with “Buy” rating. The company was downgraded on Thursday, March 16 by Wunderlich. The firm has “Neutral” rating by Ladenburg Thalmann given on Friday, November 6. The rating was maintained by Maxim Group with “Buy” on Monday, August 10.

Investors sentiment decreased to 1.17 in 2017 Q4. Its down 0.10, from 1.27 in 2017Q3. It dived, as 4 investors sold GARS shares while 8 reduced holdings. 4 funds opened positions while 10 raised stakes. 3.57 million shares or 8.15% more from 3.30 million shares in 2017Q3 were reported. Webster Retail Bank N A has invested 0% in Garrison Capital Inc. (NASDAQ:GARS). Tower Lc (Trc) reported 1,194 shares. Oppenheimer And Incorporated stated it has 35,873 shares or 0.01% of all its holdings. Wells Fargo & Mn stated it has 5,981 shares or 0% of all its holdings. Ajo Limited Partnership invested 0% of its portfolio in Garrison Capital Inc. (NASDAQ:GARS). California Pub Employees Retirement Systems has 0% invested in Garrison Capital Inc. (NASDAQ:GARS) for 43,000 shares. Blair William And Il holds 20,200 shares. Millennium Limited Liability Company holds 0% in Garrison Capital Inc. (NASDAQ:GARS) or 24,735 shares. Jpmorgan Chase owns 19,300 shares. Ares Mgmt Ltd Company accumulated 299,855 shares. Pennsylvania-based Janney Montgomery Scott Ltd has invested 0% in Garrison Capital Inc. (NASDAQ:GARS). Stephens Ar, a Arkansas-based fund reported 24,721 shares. Manufacturers Life Insur The has 1,037 shares for 0% of their portfolio. Drw Limited Liability Com has 0.37% invested in Garrison Capital Inc. (NASDAQ:GARS). Caxton accumulated 9.86% or 1.00M shares.

More news for Garrison Capital Inc. (NASDAQ:GARS) were recently published by: Seekingalpha.com, which released: “Garrison Capital’s (GARS) CEO Joseph Tansey on Q1 2018 Results – Earnings Call Transcript” on May 14, 2018. Nasdaq.com‘s article titled: “Garrison Capital Inc. Declares Second Quarter 2018 Distribution of $0.28 Per Share and Announces First Quarter 2018 …” and published on May 08, 2018 is yet another important article.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on August, 14. They expect $-0.73 EPS, down 14.06% or $0.09 from last year’s $-0.64 per share. After $-0.78 actual EPS reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -6.41% EPS growth.

Since December 11, 2017, it had 0 insider buys, and 29 selling transactions for $3.19 million activity. Shacham Sharon had sold 10,000 shares worth $152,895. $37,527 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) shares were sold by Primiano Christopher Brett. 10,000 shares were sold by Kauffman Michael, worth $100,882. On Thursday, May 10 Mirza Mansoor Raza sold $36,000 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 2,000 shares.

Karyopharm Therapeutics Inc President & CSO and an insider Sharon Shacham lately unloaded 10,000 company shares amounting to $193,870 at the avg market share price which was $19.4. She also sold 10,000 shares valued at $167,747 USD in the last month. Sharon Shacham now indirectly has ownership of 606761 shares. She also directly has ownership of 713510 shares. In total she holds a stake of 2.19%.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $1.20 billion. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $24.50’s average target is 23.24% above currents $19.88 stock price. Karyopharm Therapeutics Inc. had 38 analyst reports since August 11, 2015 according to SRatingsIntel. Bank of America downgraded the shares of KPTI in report on Tuesday, March 15 to “Underperform” rating. As per Friday, March 16, the company rating was maintained by JP Morgan. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Buy” rating by H.C. Wainwright on Tuesday, December 12. The firm earned “Buy” rating on Thursday, October 12 by Jefferies. As per Friday, June 23, the company rating was maintained by Cantor Fitzgerald. The company was maintained on Tuesday, April 10 by JP Morgan. JMP Securities maintained the shares of KPTI in report on Wednesday, March 9 with “Market Outperform” rating. The firm has “Buy” rating given on Thursday, January 11 by H.C. Wainwright. JP Morgan maintained the stock with “Overweight” rating in Monday, March 14 report. The rating was maintained by Robert W. Baird on Thursday, March 15 with “Buy”.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Karyopharm Impresses In Refractory Multiple Myeloma Trial” on May 01, 2018, also Seekingalpha.com with their article: “Your Daily Pharma Scoop: KPTI Data, Allergan Write-Off, Celgene Down On Delay” published on May 02, 2018, Globenewswire.com published: “Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock” on May 03, 2018. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q1 2018 Results – Earnings Call Transcript” published on May 10, 2018 as well as Streetinsider.com‘s news article titled: “After-Hours Stock Movers 04/30: (KPTI) (INGN) (NTRI) Higher; (CGNX) (IVAC) (RIG) Lower (more..)” with publication date: April 30, 2018.

The stock increased 0.66% or $0.13 during the last trading session, reaching $19.88. About 418,310 shares traded. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has risen 23.92% since May 22, 2017 and is uptrending. It has outperformed by 12.37% the S&P500.

Garrison Capital Inc. (NASDAQ:GARS) Institutional Positions Chart